Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial

oleh: Eugene Kim, Federico Cappuzzo, Martin Reck, Wei Zou, Mark A Socinski, Mark McCleland, Makoto Nishio, Stefanie Morris, David Shames, Meghna Das Thakur, Tony SK Mok, Howard Jack West, Robert M Jotte, Geetha Shankar

Format: Article
Diterbitkan: BMJ Publishing Group 2022-02-01

Deskripsi

No description available for this item.